# SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

> **NCT04878107** · PHASE2 · UNKNOWN · sponsor: **Wuhan University** · enrollment: 88 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib
- **DRUG:** Docetaxel injection
- **RADIATION:** SBRT
- **RADIATION:** LDRT

## Key facts

- **NCT ID:** NCT04878107
- **Lead sponsor:** Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-15
- **Primary completion:** 2022-10
- **Final completion:** 2023-10
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2022-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878107, "SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04878107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*